A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis

Journal of Neurology

Volumn 258, Issue 3, 2011, Pages 402-411

  Zwibel, Howard ^a   Pardo, Gabriel ^b   Smith, Shelly ^c   Denney, Douglas ^d   Oleen Burkey, Merrikay ^e  

^a Neuroscience Consultants   (United States)

^b MS Center of Oklahoma   (United States)

^c Commonwealth Pain Specialists ^*  (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e Teva Pharmaceuticals   (United States)

Author keywords

Adherence; Glatiramer acetate; Multiple sclerosis; Readiness; Self efficacy; Self injection

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SELF CONCEPT; SELF INJECTION; THEORETICAL MODEL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT COMPLIANCE; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SELF ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953787012     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5766-2     Document Type: Article

References (30)

1. Medical Advisory Board of the National Multiple Sclerosis Society (2005) Disease management consensus statement - treatment recommendations for physicians. US Neurology Review. Touch Briefings, London, pp 47-50
2. Perkins DO (2002) Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 63:1121-1128
3. Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P et al (2002) Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 31(Suppl3):S123-S127 (Pubitemid 35453571)
4. Krueger KP, Berger BA, Felkey B (2005) Medication adherence and persistence: a comprehensive review. Adv Ther 22:313-356 (Pubitemid 43003324)
5. Cunningham A, Gottberg K, von Koch L, Hillert J (2009) Nonadherence to interferon-beta therapy in Swedish patients with multiple sclerosis. Acta Neurol Scand 121:154-160. doi: 10.1111/j.1600-0404.2009
6. Twork S, Nippert I, Schere P, Haas J, Pohlau D, Kugler J (2007) Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin 23:1209-1215. doi: 10.1185/030079907X188125 (Pubitemid 46998430)
7. Loghman-Adham M (2003) Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 9:155-171
8. Lopez-Sanroman A, Bermejo F (2006) Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther 24(Suppl3):45-49 (Pubitemid 44326420)
9. Chia LR, Schlenk EA, Dunbar-Jacob J (2006) Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs Aging 23:191-202
10. Fraser C, Morgante L, Hadjimichael O, Vollmer T (2004) A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs 36:120-129
11. DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: metaanalysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101-2107 (Pubitemid 30482715)
12. Bruce JM, Hancock LM, Arnett P, Lynch S (2010) Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 33(3):219-227. doi: 10.1007/s10865-010-9247-y
13. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE (2001) Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 23:125-132 (Pubitemid 32488430)
14. Turner AP, Williams RM, Sloan AP, Haselkorn JK (2009) Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol 54:116-121. doi:10.1037/a0014460
15. Holland N, Wiesel P, Cavallo P, Edwards C, Halper J, Kalb R et al (2001) Adherence to disease-modifying therapy in multiple sclerosis: Part I. Rehabil Nurs 26:172-176
16. Tremlett HL, Oger J (2003) Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 61:551-554 (Pubitemid 37025380)
17. O'Rourke KE, Hutchinson M (2005) Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 11:46-50 (Pubitemid 40259974)
18. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA (2010) Impact of adherence to interferons in the treatment of multiple sclerosis. Clin Drug Investig 30:89-100. doi:1173-2563/10/0002-0089/$49.95/0
19. Prochaska JO, DiClemente CC (1983) Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 51:390-395
20. Prochaska JO, Velicer WF (1997) The transtheoretical model of health behavior change. Am J Health Promot 12:38-48 (Pubitemid 27382892)
21. Prochaska JO, Velicer WF, Rossi JS, Goldstein MG, Marcus BH, Rakowski W et al (1994) Stages of change and decisional balance for 12 problem behaviors. Health Psychol 13:39-46
22. Kallings LV, Leijon ME, Kowlski J, Hellenius ML, Stahle A (2009) Self-reported adherence: a method for evaluating prescribed physical activity in primary health care patients. J Phys Act Health 6:483-492
23. Holland N, Wiesel P, Cavallo P, Edwards C, Halper J, Kalb R et al (2001) Adherence to disease-modifying therapy in multiple sclerosis: Part II. Rehabil Nurs 26:221-226
24. Fraser C, Hadjimichael O, Vollmer T (2001) Predictors of adherence to Copaxone therapy in individuals with relapsingremitting multiple sclerosis. J Neurosci Nurs 33:231-239
25. Schwartz CE, Coulthard-Morris L, Zeng Q, Retzlaff P (1996) Measuring self-efficacy in people with multiple sclerosis: a validation study. Arch Phys Med Rehabil 77:394-398
26. Lee R, Taira DA (2005) Adherence to oral hypoglycemic agents in Hawaii. Prev Chronic Dis 2:A09
27. Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W (1999) Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 26:2114-2122 (Pubitemid 29487003)
28. Rio J, Porcel J, Tellez N, Sanchez-Betancourt A, Tintore M, Arevalo MJ et al (2005) Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11:306-309 (Pubitemid 40775187)
29. Fraser C, Hadjimichael O, Vollmer T (2003) Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs 35:163-170
30. Bruce JM, Hancock LM, Lynch SG (2010) Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler 16:112-120